RU2013145283A - Новые антагонисты рецептора интерлейкина-1 - Google Patents
Новые антагонисты рецептора интерлейкина-1 Download PDFInfo
- Publication number
- RU2013145283A RU2013145283A RU2013145283/10A RU2013145283A RU2013145283A RU 2013145283 A RU2013145283 A RU 2013145283A RU 2013145283/10 A RU2013145283/10 A RU 2013145283/10A RU 2013145283 A RU2013145283 A RU 2013145283A RU 2013145283 A RU2013145283 A RU 2013145283A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- peptide
- amino acid
- acid sequence
- identity
- Prior art date
Links
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 32
- 150000001413 amino acids Chemical group 0.000 claims abstract 30
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims abstract 27
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims abstract 21
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims abstract 21
- 239000012634 fragment Substances 0.000 claims abstract 15
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims abstract 14
- 125000000539 amino acid group Chemical group 0.000 claims abstract 8
- 102000005962 receptors Human genes 0.000 claims abstract 8
- 108020003175 receptors Proteins 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 208000027866 inflammatory disease Diseases 0.000 claims 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 206010009887 colitis Diseases 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000000412 dendrimer Substances 0.000 claims 2
- 229920000736 dendritic polymer Polymers 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 206010042276 Subacute endocarditis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000003441 Transfusion reaction Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000031018 biological processes and functions Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 201000008269 immune-complex glomerulonephritis Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000002314 neuroinflammatory effect Effects 0.000 claims 1
- 230000007514 neuronal growth Effects 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 201000004338 pollen allergy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 206010040400 serum sickness Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170120 | 2011-03-14 | ||
| DKPA201170120 | 2011-03-14 | ||
| PCT/DK2012/000022 WO2012122985A1 (en) | 2011-03-14 | 2012-03-14 | Antagonists of the interleukin- 1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013145283A true RU2013145283A (ru) | 2015-04-20 |
Family
ID=45876525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013145283/10A RU2013145283A (ru) | 2011-03-14 | 2012-03-14 | Новые антагонисты рецептора интерлейкина-1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9359405B2 (enExample) |
| EP (1) | EP2686431B1 (enExample) |
| JP (1) | JP6120782B2 (enExample) |
| KR (1) | KR20140012127A (enExample) |
| CN (1) | CN103476933B (enExample) |
| AU (1) | AU2012228769B2 (enExample) |
| BR (1) | BR112013023309A2 (enExample) |
| CA (1) | CA2828504A1 (enExample) |
| ES (1) | ES2600616T3 (enExample) |
| MX (1) | MX2013010171A (enExample) |
| RU (1) | RU2013145283A (enExample) |
| WO (1) | WO2012122985A1 (enExample) |
| ZA (1) | ZA201306744B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853150B2 (en) | 2010-07-29 | 2014-10-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I antagonists |
| KR102017026B1 (ko) * | 2013-01-10 | 2019-09-02 | (주) 수파드엘릭사 | 염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물 |
| SG10201707477SA (en) | 2013-03-13 | 2017-10-30 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery |
| AU2014274044B2 (en) * | 2013-05-31 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Methods of using IL-1 antagonists to treat Alzheimer's Disease |
| CN104711214B (zh) * | 2015-04-09 | 2019-02-12 | 武汉联程生物科技有限公司 | 一种大肠杆菌bbm2015001菌株及其用途 |
| WO2017063657A1 (en) | 2015-10-14 | 2017-04-20 | Phlogo Aps | Il1ra-derived peptide antagonist |
| SG11201907159SA (en) * | 2017-02-16 | 2019-09-27 | Xbiotech Inc | Treatment of hidradenitis suppurativa |
| WO2019200213A1 (en) * | 2018-04-12 | 2019-10-17 | Mayo Foundation For Medical Education And Research | Methods for guiding therapy decisions in seizure disorders |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| AU2021455992A1 (en) * | 2021-07-13 | 2024-01-18 | Serodus Aps | Il1ra derived peptides for treatment of diabetic nephropathy |
| CN114177295B (zh) * | 2021-12-16 | 2023-09-19 | 上海市第五人民医院 | 白细胞介素1受体拮抗剂治疗非酒精性脂肪性肝病的应用 |
| CN116144668A (zh) * | 2023-02-13 | 2023-05-23 | 杭州吉倍思生物制药有限公司 | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 |
| JP7786006B1 (ja) * | 2023-04-14 | 2025-12-15 | メルク・シャープ・アンド・ドーム・エルエルシー | インターロイキン－１ベータを捕捉するための環状ペプチド |
| WO2025101453A1 (en) * | 2023-11-07 | 2025-05-15 | University Of Washington | De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU222810B1 (hu) | 1988-05-27 | 2003-11-28 | Synergen Inc. | Interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, a szekvenciákat tartalmazó rekombináns DNS-vektorok, a vektort tartalmazó gazdasejtek és rekombináns GT-10-il-1i-2A DNS molekula |
| US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| CZ1497A3 (en) * | 1994-07-05 | 1997-05-14 | Steeno Res Group As | Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
| IT1270662B (it) | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
| DE19919148A1 (de) * | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
| HUP0400698A3 (en) * | 2001-02-06 | 2006-01-30 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| MXPA03007316A (es) * | 2001-02-19 | 2003-12-04 | Merck Patent Gmbh | Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida. |
| AU2002332931A1 (en) | 2001-09-06 | 2003-03-24 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| JP2005528107A (ja) * | 2002-05-31 | 2005-09-22 | シェジェン ピーティーワイ リミテッド | 膜転位置配列由来の自己合体または自己凝集キメラタンパク質 |
| US20050159590A1 (en) | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| WO2005086695A2 (en) | 2004-03-04 | 2005-09-22 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonist and uses thereof |
| US7674464B2 (en) * | 2004-03-04 | 2010-03-09 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonists |
| LT1729810T (lt) | 2004-04-02 | 2018-11-26 | Swedish Orphan Biovitrum Ab (Publ) | Il-1ra agregacijos sumažinimo būdas |
| WO2005105830A1 (en) | 2004-05-05 | 2005-11-10 | Valorisation-Recherche, Societe En Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US20090048161A1 (en) | 2005-05-05 | 2009-02-19 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| AU2008289552B2 (en) | 2007-08-16 | 2014-10-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| WO2009048961A1 (en) | 2007-10-08 | 2009-04-16 | Anaphore, Inc. | Trimeric il-1ra |
| CN101255197B (zh) * | 2008-03-28 | 2012-01-25 | 浙江海正药业股份有限公司 | 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用 |
| EP3178835B1 (en) * | 2009-02-03 | 2019-04-10 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
-
2012
- 2012-03-14 KR KR1020137026679A patent/KR20140012127A/ko not_active Withdrawn
- 2012-03-14 CN CN201280013172.1A patent/CN103476933B/zh not_active Expired - Fee Related
- 2012-03-14 ES ES12710122.8T patent/ES2600616T3/es active Active
- 2012-03-14 WO PCT/DK2012/000022 patent/WO2012122985A1/en not_active Ceased
- 2012-03-14 US US14/003,824 patent/US9359405B2/en active Active
- 2012-03-14 CA CA2828504A patent/CA2828504A1/en not_active Abandoned
- 2012-03-14 MX MX2013010171A patent/MX2013010171A/es not_active Application Discontinuation
- 2012-03-14 BR BR112013023309A patent/BR112013023309A2/pt not_active IP Right Cessation
- 2012-03-14 JP JP2013558307A patent/JP6120782B2/ja active Active
- 2012-03-14 EP EP12710122.8A patent/EP2686431B1/en active Active
- 2012-03-14 RU RU2013145283/10A patent/RU2013145283A/ru not_active Application Discontinuation
- 2012-03-14 AU AU2012228769A patent/AU2012228769B2/en not_active Ceased
-
2013
- 2013-09-09 ZA ZA2013/06744A patent/ZA201306744B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140073556A1 (en) | 2014-03-13 |
| CA2828504A1 (en) | 2012-09-20 |
| BR112013023309A2 (pt) | 2017-09-19 |
| ES2600616T3 (es) | 2017-02-10 |
| MX2013010171A (es) | 2013-11-20 |
| EP2686431B1 (en) | 2016-08-03 |
| WO2012122985A1 (en) | 2012-09-20 |
| AU2012228769B2 (en) | 2016-09-08 |
| AU2012228769A1 (en) | 2013-10-10 |
| CN103476933B (zh) | 2016-04-13 |
| JP6120782B2 (ja) | 2017-04-26 |
| US9359405B2 (en) | 2016-06-07 |
| NZ615710A (en) | 2015-10-30 |
| CN103476933A (zh) | 2013-12-25 |
| ZA201306744B (en) | 2014-11-26 |
| KR20140012127A (ko) | 2014-01-29 |
| JP2014510082A (ja) | 2014-04-24 |
| EP2686431A1 (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013145283A (ru) | Новые антагонисты рецептора интерлейкина-1 | |
| JP2014510082A5 (enExample) | ||
| Almaaytah et al. | Scorpion venom peptides with no disulfide bridges: a review | |
| Shi | Dock protein family in brain development and neurological disease | |
| AU2005279308B2 (en) | Protease resistant human and non-human HMGB1 Box-A mutants and their therapeutic/diagnostic use | |
| JP2012515778A5 (enExample) | ||
| EA035973B9 (en) | Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same | |
| JP2015519878A5 (enExample) | ||
| SI2699601T1 (en) | PROTITOLIC POLYPETIDES AS THE CD40 ANTAGONISTS | |
| EA201101553A1 (ru) | Полипептид, деградирующий углеводы, и его применения | |
| EA201300054A1 (ru) | Полипептид, обладающий активностью бета-глюкозидазы, и его применение | |
| EA201201126A1 (ru) | Полипептид, обладающий активностью целлобиогидролазы, и его применение | |
| JP2015525768A5 (enExample) | ||
| EA201300060A1 (ru) | Полипептид, обладающий или содействующий активности деградации углеводного материала, и его применение | |
| HK1223019A1 (zh) | 用於治疗室内尘蟎过敏的连续重叠肽 | |
| BR112017022009A2 (pt) | ?composto, método de produção e síntese do mesmo e seu uso, composição e conjunto terapêutico? | |
| NZ630536A (en) | Therapeutic agent or prophylactic agent for dementia | |
| FI2956471T3 (fi) | Il-1-beetan estäjän koostumus ja sen käyttö | |
| Pang et al. | Identification and characterization of the lamprey high-mobility group box 1 gene | |
| FI20115870A0 (fi) | Neuroprotektiiviset soluihin tunkeutuvat peptidit | |
| JP2014510101A5 (enExample) | ||
| Flores‐Solis et al. | Solution structure and antiparasitic activity of scorpine‐like peptides from Hoffmannihadrurus gertschi | |
| RU2016107873A (ru) | Пептиды | |
| JP2019510737A5 (enExample) | ||
| WO2018152172A9 (en) | Glp-1r agonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161206 |